Laura A. Magee

TL;DR: The purpose of this document is to update ISSHP thinking on this subject and recommend that a broad definition, at times not including proteinuria, could be applied for the clinical definition of pre-eclampsia whilst the inclusion of proteinuria would ensure more specificity around the diagnosis when reporting clinical criteria for patients enrolled in scientific research.

TL;DR: The cause(s) of preeclampsia and the optimal clinical management of the hypertensive disorders of pregnancy remain uncertain; therefore, it is recommended that every hypertensive pregnant woman be offered an opportunity to participate in research, clinical trials, and follow-up studies.

TL;DR: A first step would be to subdivide preeclampsia into early‐onset disease (< 34 + 0 weeks') and late onset disease (> 34 +0 weeks').

TL;DR: In this paper, a set of recommendations from ISSHP is designed to assist clinicians throughout the world in the recognition and management of the hypertensive disorders of pregnancy; the document includes sections written by those working in low and middle income countries so as to ensure applicability in all parts of the world.

TL;DR: This guideline summarizes the quality of the evidence to date and provides a reasonable approach to the diagnosis, evaluation, and treatment of the hypertensive disorders of pregnancy (HDP).